Loading
Life sciences · Journal article
Revista Argentina De Cardiología · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide, and low-density lipoprotein cholesterol (LDL-C) is the primary causal and modifiable risk factor.Available lipid-lowering therapies-statins, ezetimibe, anti-PCSK9 monoclonal antibodies, and RNA interference-have been shown to reduce cardiovascular events, but they require long-term administration and are limited by efficacy, adherence, cost, and access.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is, to date, the most genetically validated target for the development of in vivo gene-editing strategies aimed at achieving a permanent reduction in LDL-C through a single therapeutic administration.This review describes the biology of PCSK9, the available gene-editing platforms-CRISPR-Cas9, base editing, and primer editing-and their delivery to hepatocytes via lipid nanoparticles.It summarizes preclinical data and ongoing clinical trials (VERVE-101, VERVE-102, and YOLT-101) showing sustained, dose-dependent reductions in LDL-C following a single infusion, with acceptable short-term safety profiles.Finally, the long-term safety, regulatory, economic, and ethical challenges that will determine the eventual translation of this technology into routine clinical practice are discussed.